CytomX Therapeutics (CTMX) Receivables - Net (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Receivables - Net data on file, last reported at $646000.0 in Q1 2026.

• Quarterly Receivables - Net fell 66.97% year-over-year to $646000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646000.0 (down 66.97% YoY) and the FY2025 annual result came in at $2.0 million, down 35.13% from the prior year.
• Receivables - Net slipped to $646000.0 in Q1 2026, from $900000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $36.0 million in Q4 2022 to a low of $646000.0 in Q1 2026.
• A 5-year average of $4.4 million and a median of $1.9 million in 2025 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net jumped 4398.25% — and 2023, when it plunged 93.89%.
• Tracing CTMX's Receivables - Net over 5 years: stood at $36.0 million in 2022, then sank by 93.89% to $2.2 million in 2023, then slumped by 50.0% to $1.1 million in 2024, then dropped by 18.18% to $900000.0 in 2025, then slipped by 28.22% to $646000.0 in 2026.
• The last three Receivables - Net figures came in at $646000.0 (Q1 2026), $900000.0 (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.